Pharmaceuticals 23 November 2025

Johnson & Johnson Stock (JNJ) Near Record Highs: Halda Deal, Spin‑Off Plans and Talc Risks on November 28, 2025

Johnson & Johnson is closing out 2025 as one of the standout “defensive” winners in the U.S. market. The stock is trading just below a fresh 52‑week high around $205–$208 per share, giving the healthcare giant a market capitalization of roughly $500 billion.FinancialContent

28 November 2025

NYSE:JNJ·Pharmaceuticals·Stock Market

Pfizer Stock Today (PFE), November 28, 2025: Guggenheim Upgrade, Norges Bank Stake and a 6.7% Dividend Yield

Pfizer stock is trading around $25.8 per share in late morning trading on Friday, November 28, 2025, up roughly 0.3% from yesterday’s close near $25.72.MarketBeat

28 November 2025

NYSE:PFE·Pharmaceuticals·Stock Market

GSK plc Stock Today, 28 November 2025: Buybacks, ‘Hold’ Ratings and Pipeline Momentum Keep Shares Near Highs

GSK plc is drifting quietly higher on Friday, 28 November 2025, with investors digesting a fresh “Hold” consensus from Wall Street, another round of share buybacks and a still‑busy drug pipeline that has pushed the stock close to 12‑month highs.

28 November 2025

LSE:GSK.L·Pharmaceuticals·Stock Market

Novo Nordisk (NVO) Stock Rebounds as Wegovy Upgrade and Medicare Deal Ease Pricing Fears – 26 November 2025

Novo Nordisk A/S stock is staging a sharp rebound today, 26 November 2025, as investors digest a trio of major developments: an FDA filing for a higher-dose version of its blockbuster obesity drug Wegovy, clarity on steep—but largely expected—Medicare price cuts for Ozempic and Wegovy, and fresh enthusiasm around its next‑generation obesity candidate amycretin.

26 November 2025

CPH:NOVO-B·NYSE:NVO·Pharmaceuticals·Stock Market

Pfizer Stock Today, November 26, 2025: Obesity Bet, Cancer Breakthrough and Legal Risks Shape PFE’s Outlook

Pfizer Inc. spent Wednesday trading slightly lower despite a stream of fresh headlines that cut both ways for sentiment. The stock hovered around $25.7, giving back a fraction of Tuesday’s nearly 2% gain, as investors weighed upbeat news on obesity drugs, cancer treatment and vaccines against ongoing legal and regulatory risks. MarketScreener+1

26 November 2025

NYSE:PFE·Pharmaceuticals

Merck (MRK) Stock Today – November 26, 2025: Keytruda Wins, Analyst Upgrades and Big Money Buying Keep Shares Near Record Highs

Merck & Co., Inc. spent Wednesday trading just below fresh 52‑week highs, as Wall Street continues to digest a powerful mix of positive drug news, upbeat earnings, and a wave of analyst upgrades and institutional buying.

26 November 2025

NYSE:MRK·Pharmaceuticals·Stock Market

Pfizer (PFE) Stock Today, November 26, 2025: Options Surge, Obesity Bet and Cancer Win Shape the Outlook

Pfizer Inc. heads into Wednesday, November 26, 2025 with its share price sitting just under the top of its recent trading range and a narrative that looks very different from the COVID‑era boom and bust.

26 November 2025

NYSE:PFE·Pharmaceuticals·Stock Market

Merck (MRK) Stock Soars on FDA Keytruda Approval and Wells Fargo Upgrade – 25 November 2025

Merck & Co., Inc. is back in the market’s spotlight this Tuesday, with the pharmaceutical giant’s shares extending a powerful rally fuelled by fresh regulatory wins and a major Wall Street upgrade.

25 November 2025

NYSE:MRK·Pharmaceuticals·Stock Market

NVO Stock Today: Novo Nordisk Rebounds on New Weight‑Loss Drug Data After Alzheimer’s Blow (Nov. 25, 2025)

As of late‑afternoon trading on Tuesday, November 25, 2025, Novo Nordisk A/S American Depositary Receipts, ticker NVO on the NYSE, were changing hands at about $47.08, up $2.11 on the session — a gain of roughly 4.7% versus Monday’s close.

25 November 2025

NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly (LLY) Stock Today: $1 Trillion Pharma Giant Extends Rally on Bernstein Upgrade and GLP‑1 Momentum – 25 November 2025

INDIANAPOLIS — November 25, 2025 — Eli Lilly and Company continued its remarkable run on Tuesday, as the first-ever $1 trillion pharmaceutical company saw its stock climb again on the back of fresh analyst upgrades, intensifying obesity-drug momentum and ongoing institutional and retail interest.

25 November 2025

NYSE:LLY·Pharmaceuticals·Stock Market

German Stock Market Today: DAX Rebounds as Bayer Surges on Stroke‑Drug Breakthrough – 24 November 2025

Germany’s stock market kicked off the new week with a relief rally on Monday, 24 November 2025. The blue‑chip DAX 40 climbed around 0.7% to close just above 23,200 points, helped by a double‑digit jump in Bayer and renewed optimism about global interest‑rate cuts, even as the latest Ifo business climate index once again highlighted the fragility of Europe’s largest economy. Investing

25 November 2025

Pharmaceuticals·Stock Market·XETRA:BAYN

SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

Shares of Sarepta Therapeutics head into Tuesday’s session trying to build on a rare rally, as investors digest a positive safety update for its experimental RNA therapy SRP‑1003 and weigh it against fresh FDA warnings and trial setbacks tied to its gene therapy Elevidys.

25 November 2025

Biotechnology·NASDAQ:ARWR·NASDAQ:SRPT·Pharmaceuticals·Stock Market

VKTX Stock Today, November 25, 2025: Can Viking Therapeutics Keep Riding the Obesity Drug Wave?

Viking Therapeutics heads into the Tuesday, November 25, 2025 session trading in the mid‑$30s, still digesting last week’s major milestone: the company has finished enrolling patients in its pivotal Phase 3 obesity trial VANQUISH‑1 ahead of schedule and above its original target. Viking Therapeutics InvestorRoom

25 November 2025

NASDAQ:VKTX·Pharmaceuticals·Stock Market

MRK Stock Today: Merck Jumps on Wells Fargo Upgrade and Keytruda Momentum (November 24, 2025)

Merck & Co., Inc. is in rally mode on Monday, November 24, 2025. By early afternoon, MRK stock is trading around $101–$102 per share, up roughly 3.5–3.8% on the day, near its highest levels of 2025 and within a few percent of its 52‑week high. StockAnalysis

24 November 2025

NYSE:MRK·Pharmaceuticals·Stock Market

BMY Stock Soars on Factor XIa Catalyst and Hematology Investor Event (Nov. 24, 2025)

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security.

24 November 2025

NYSE:BMY·Pharmaceuticals

Bayer Aktie (BAYN) Soars Over 10% on Stroke Drug Breakthrough – All Key News for 24 November 2025

Bayer’s share price is having its strongest single session in a long time. On Monday, 24 November 2025, the Bayer Aktie on Xetra jumped roughly 9–11% to trade around €30–31, briefly touching a new year high near €31 and closing a little above €30.5 according to German market data.finanzen.net+1

24 November 2025

Pharmaceuticals·XETRA:BAYN

Eli Lilly Hits $1 Trillion: Weight‑Loss Drugs Turn a 150‑Year‑Old Pharma Into a Tech‑Sized Giant

Eli Lilly has done something no other health‑care company has ever achieved: it has joined the $1 trillion market‑capitalization club, a group previously dominated almost entirely by technology giants like Apple, Microsoft and Nvidia.

24 November 2025

NYSE:LLY·Pharmaceuticals·Stock Market·Technology

Novo Nordisk Stock Plunges After Alzheimer’s Drug Failure: NVO Price, News and Outlook Today (24 November 2025)

Danish pharma giant Novo Nordisk is under intense pressure today after its high‑profile Alzheimer’s trials for semaglutide failed, sending the stock to multi‑year lows and capping a brutal year for NVO shareholders.

24 November 2025

NASDAQ:NVO·Pharmaceuticals·Stock Market

Recursion Pharmaceuticals (RXRX) Stock Today: ‘Hold’ Rating, New Institutional Buying and AI Drug Discovery Hype — November 23, 2025

Recursion Pharmaceuticals Inc. closed Friday, November 21, 2025, at $4.17, up 8.31% on the day after bouncing off the low‑$3 range earlier in the week. Volume was heavy at roughly 33 million shares, and the stock now trades near the bottom of its 52‑week range of $3.79–$12.36.StockInvest+1

24 November 2025

Artificial Intelligence·NASDAQ:RXRX·Pharmaceuticals·Stock Market

Tonix Pharmaceuticals Stock on November 23, 2025: Tonmya Launch, Bigger Buyback, and a $400M ATM Shape the TNXP Trade

Tonix Pharmaceuticals Holding Corp. heads into Sunday, November 23, 2025, with its first commercial fibromyalgia drug now on pharmacy shelves, a beefed‑up share repurchase program, and a sharply expanded at‑the‑market equity facility. Together, those moves are redefining the risk‑reward profile of this small‑cap biotech just as investors focus on how quickly new product Tonmya can ramp. Tonix Pharmaceuticals Holding Corp.+2Investing.com+2

23 November 2025

NASDAQ:TNXP·Pharmaceuticals·Stock Market

Pharmaceuticals 23 November 2025 - 28 November 2025